CardioDx Raises More than $40M in Series E Round | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cardiovascular genomics test firm CardioDx has raised more than $40 million in a Series E financing round.

David Levison, CEO of the Palo Alto, Calif.-based company confirmed to GenomeWeb Daily News that the round raised more than $40 million, but he declined to provide a more exact figure. However, a document filed with the US Securities and Exchange Commission last week claimed the company has brought in $57.5 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.